REGULATORY

• Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
  August 29, 2023

• Kazunari Asanuma to Lead MHLW Health Policy Bureau
  August 29, 2023

• MHLW to Seek Funds for Survey to Streamline Generic Manufacturing: FY2024 Request
  August 28, 2023

• MHLW to Book Budget to Launch Regulatory Advisory Center for Pediatric, Orphan Meds for FY2024
  August 28, 2023

• MHLW to Seek 33.7 Trillion Yen Budget for FY2024
  August 28, 2023

• Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
  August 28, 2023

• Shunichi Kuryu to Take Helm at New Infectious Disease Agency
  August 28, 2023

• MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
  August 25, 2023

• Japan Grants Orphan Tag to Efzofitimod, 3 More APIs
  August 25, 2023

• Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
  August 24, 2023

• Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
  August 24, 2023

• Lyfnua to Get 7.7% Price Cut in November, Retevmo Analysis Results Reported: CEA
  August 24, 2023

• Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
  August 24, 2023

• Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
  August 24, 2023

• Japan Approves Enhertu’s NSCLC Use, More Label Expansions
  August 24, 2023

• Novo’s Obesity Med Wegovy Skips Listing Again in August
  August 24, 2023

• Japan Designates Loxoprofen Cold Meds as Behind the Counter Drugs
  August 23, 2023

• Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
  August 23, 2023

• Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
  August 23, 2023

• MHLW Generics Study Group Discusses Yardsticks to Gauge Manufacturers’ Efforts towards Stabilizing Supplies
  August 22, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 73
• 74
• 75
• 76
• 77
• 78
• 79
• 80
• 81
• …
• Next ›
• 最終 »